Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treatment of hyperglycemia

A composition and compound technology, applied in the direction of drug combination, active ingredients of heterocyclic compounds, blood diseases, etc.

Inactive Publication Date: 2015-07-29
CELLIXBIO PTE LTD
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite strong experimental evidence that oxidative stress can determine the onset and course of advanced diabetic complications, there is still controversy as to whether elevated oxidative stress in hyperglycemia is merely an association rather than a causation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treatment of hyperglycemia
  • Compositions and methods for treatment of hyperglycemia
  • Compositions and methods for treatment of hyperglycemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0154] The comparison of the compound of formula I (1-3) and eicosapentaenoic acid (EPA) solubility in water

[0155]Measurement of aqueous solubility of test compounds is accomplished by methods well known to those skilled in the art. Specifically, distilled water was added several times in small amounts to a weighed amount of the test compound of the example compound formula I (1-3) until a clear solution was obtained. Measure the total volume of the solution. Water solubility was calculated by dividing the weight of the salt in milligrams (mg) by the volume of the solution in mL. When measured by the above method, the water solubility of the compound of formula I (1-3) was determined to be 68.6 mg / ml. Likewise, the water solubility of EPA was found to be <0.2 mg / mL. Thus, compounds of formula I (1-3) are at least 260 times more water soluble than EPA itself. This clearly demonstrates the unexpectedly high bioavailability of the composition of the invention. When a high...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to View More

Abstract

The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for the treatment of hyperglycemia may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia, cardiovascular complications, and post prandial hyperglycemia.

Description

[0001] priority [0002] This application claims the benefit of Indian Provisional Patent Application No. 1811 / CHE / 2012, filed May 8, 2012, the entire disclosure of which is relied upon for all purposes and is incorporated by reference in its entirety In this application. technical field [0003] The present disclosure relates generally to compounds and compositions useful in the treatment of hyperglycemia, diabetes and insulin resistance. More specifically, the present invention relates to the treatment of a subject with a pharmaceutically acceptable dose of a compound, crystal, ester, stereoisomer, enantiomer, salt, hydrate, prodrug, or mixture thereof. Background technique [0004] Multiple metabolic syndromes are defined as multiple severe metabolic disorders that increase the risk of cardiovascular disease (CVD), still the most important cause of death in the Western world, and type 2 diabetes. Multiple metabolic syndrome, also known as insulin resistance syndrome, sy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D211/46C07D409/14A61K31/445A61K31/4535A61P3/10A61P5/50A61P3/06A61P3/04A61P7/00A61P9/00A61P7/12A61P9/06A61P9/10A61P25/00A61P13/12
CPCC07D211/46C07D409/12C07D409/14A61P3/00A61P3/02A61P3/04A61P3/06A61P3/08A61P3/10A61P5/50A61P7/00A61P7/12A61P9/00A61P9/06A61P9/10A61P9/14A61P13/00A61P13/12A61P25/00
Inventor M·坎杜拉
Owner CELLIXBIO PTE LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com